Recombinant human thrombomodulin suppresses experimental abdominal aortic aneurysms induced by calcium chloride in mice

Annals of Surgery

Volumn 258, Issue 6, 2013, Pages 1103-1110

  Lai, Chao Han ^a,b,c   Shi, Guey Yueh ^b,d   Lee, Fang Tzu ^b,d   Kuo, Cheng Hsiang ^b,d   Cheng, Tsung Lin ^b,d   Chang, Bi Ing ^b,d   Ma, Chih Yuan ^b,d   Hsu, Fu Chih ^b,d   Yang, Yu Jen ^b,c   Wu, Hua Lin ^b,d  

^a Institute of Clinical Medicine   (Taiwan)

^b Cardiovascular Research Center   (Taiwan)

^c Departments of Surgery   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

abdominal aortic aneurysm; high mobility group box 1; inflammation; receptor for advanced glycation end product; thrombomodulin

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CALCIUM CHLORIDE; GELATINASE A; GELATINASE B; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; RECOMBINANT THROMBOMODULIN; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL AORTA ANEURYSM; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTICLE; BLOOD VESSEL CALCIFICATION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; SHORT COURSE THERAPY; VASCULITIS;

ANIMALS; AORTIC ANEURYSM, ABDOMINAL; CALCIUM CHLORIDE; MICE; MICE, INBRED C57BL; RECEPTORS, IMMUNOLOGIC; RECOMBINANT PROTEINS; THROMBOMODULIN;

EID: 84888137538     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31827df7cb     Document Type: Article

References (40)

1. Golledge J, Muller J, Daugherty A, et al. Abdominal aortic aneurysm: pathogenesis and implications for management. Arterioscler Thromb Vasc Biol. 2006;26:2605-2613.
2. Miyake T, Morishita R. Pharmacological treatment of abdominal aortic aneurysm. Cardiovasc Res. 2009;83:436-443.
3. Brewster DC, Cronenwett JL, Hallett JW, Jr, et al. Guidelines for the treatment of abdominal aortic aneurysms. Report of a subcommittee of the Joint Council of the American Association for Vascular Surgery and Society for Vascular Surgery. J Vasc Surg. 2003;37:1106-1117.
4. Fujita T. AGE/RAGE axis in the development of abdominal aortic aneurysm. Ann Surg. 2010;252:203-205.
5. Baxter BT, Terrin MC, Dalman RL. Medical management of small abdominal aortic aneurysms. Circulation. 2008;117:1883-1889.
6. Daugherty A, Cassis LA. Mouse models of abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2004;24:429-434.
7. WaltonLJ, Franklin IJ,Bayston T, et al. Inhibition of prostaglandinE2 synthesis in abdominal aortic aneurysms: implications for smooth muscle cell viability, inflammatory processes, and the expansion of abdominal aortic aneurysms. Circulation. 1999;100:48-54.
8. ShimizuK,Mitchell RN, Libby P. Inflammation and cellular immune responses in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2006;26:987-994.
9. Sun J, Sukhova GK, Yang M, et al. Mast cells modulate the pathogenesis of elastase-induced abdominal aortic aneurysms in mice. J Clin Invest. 2007;117:3359-3368.
10. Esmon C. Do-all receptor takes on coagulation, inflammation. Nat Med. 2005;11:475-477.
11. Van deWouwer M, Collen D, Conway EM. Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol. 2004;24:1374-1383.
12. Conway EM, Van de Wouwer M, Pollefeyt S, et al. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. J ExpMed. 2002;196:565-577.
13. Van de Wouwer M, Plaisance S, De Vriese A, et al. The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis. J Thromb Haemost. 2006;4:1813-1824.
14. Abeyama K, Stern DM, Ito Y, et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest. 2005;115:1267-1274.
15. Rauvala H, Rouhiainen A. Physiological and pathophysiological outcomes of the interactions of HMGB1 with cell surface receptors. Biochim Biophys Acta. 2010;1799:164-170.
16. Schmidt AM, Yan SD, Yan SF, et al. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest. 2001;108:949-955.
17. Ito T, Kawahara K, Okamoto K, et al. Proteolytic cleavage of high mobility group box 1 protein by thrombin-thrombomodulin complexes. Arterioscler Thromb Vasc Biol. 2008;28:1825-1830.
18. Huang HC, Shi GY, Jiang SJ, et al. Thrombomodulin-mediated cell adhesion: involvement of its lectin-like domain. J Biol Chem. 2003;278: 46750-46759.
19. Shi CS, Shi GY, Hsiao SM, et al. Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharideinduced inflammatory response. Blood. 2008;112:3661-3670.
20. Li YH, Liu SL, Shi GY, et al. Thrombomodulin plays an important role in arterial remodeling and neointima formation in mouse carotid ligation model. Thromb Haemost. 2006;95:128-133.
21. Wei HJ, Li YH, Shi GY, et al. Thrombomodulin domains attenuate atherosclerosis by inhibiting thrombin-induced endothelial cell activation. Cardiovasc Res. 2011;92:317-327.
22. Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol. 2011;29:139-162.
23. Ito T, Maruyama I. Thrombomodulin: protectorate God of the vasculature in thrombosis and inflammation. J Thromb Haemost. 2011;9(suppl 1):168-173.
24. Chiou AC, Chiu B, Pearce WH. Murine aortic aneurysm produced by periarterial application of calcium chloride. J Surg Res. 2001;99:371-376.
25. Longo GM, Xiong W, Greiner TC, et al. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest. 2002;110:625-632.
26. Xiong W, MacTaggart J, Knispel R, et al. Blocking TNF-alpha attenuates aneurysm formation in a murine model. J Immunol. 2009;183:2741-2746.
27. Kaneko H, Anzai T, Morisawa M, et al. Resveratrol prevents the development of abdominal aortic aneurysm through attenuation of inflammation, oxidative stress, and neovascularization. Atherosclerosis. 2011;217:350-357.
28. Yoshimura K, Aoki H, Ikeda Y, et al. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat Med. 2005;11:1330-1338.
29. Kohno T, Anzai T, Kaneko H, et al. High-mobility group box 1 protein blockade suppresses development of abdominal aortic aneurysm. J Cardiol. 2012;59:299-306.
30. Isenburg JC, Simionescu DT, Starcher BC, et al. Elastin stabilization for treatment of abdominal aortic aneurysms. Circulation. 2007;115:1729-1737.
31. van Beijnum JR, BuurmanWA, Griffioen AW. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis. 2008;11:91-99.
32. Yang H, Wang H, Czura CJ, et al. The cytokine activity of HMGB1. J Leukoc Biol. 2005;78:1-8.
33. Sims GP, Rowe DC, Rietdijk ST, et al. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol. 2010;28:367-388.
34. Yan SF, Yan SD, Ramasamy R, et al. Tempering the wrath of RAGE: an emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation. Ann Med. 2009;41:408-422.
35. Zhang F, Kent KC, Yamanouchi D, et al. Anti-receptor for advanced glycation end products therapies as novel treatment for abdominal aortic aneurysm. Ann Surg. 2009;250:416-423.
36. Zhang F, Banker G, Liu X, et al. The novel function of advanced glycation end products in regulation of MMP-9 production. J Surg Res. 2011;171:871-876.
37. Bierhaus A, Nawroth PP. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetesmellitus and its complications. Diabetologia. 2009;52:2251-2263.
38. Hofmann Bowman M, Wilk J, Heydemann A, et al. S100A12 mediates aortic wall remodeling and aortic aneurysm. Circ Res. 2010;106:145-154.
39. Basalyga DM, Simionescu DT, Xiong W, et al. Elastin degradation and calcification in an abdominal aorta injury model: role of matrix metalloproteinases. Circulation. 2004;110:3480-3487.
40. Jones A, Deb R, Torsney E, et al. Rosiglitazone reduces the development and rupture of experimental aortic aneurysms. Circulation. 2009;119:3125-3132.